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Background: Insulin resistance is manifested by decreased effect of fixed quantity of insulin on 
glucose metabolism leading to type 2 diabetes mellitus. Visceral obesity has been positively 
correlated with insulin resistance but its mechanism is not fully defined. Insulin resistance may be 
the consequence of adipocytokines including visfatin and resistin. This study was designed to see the 
effect of thiazolidinediones on levels of resistin in insulin resistant rats. Methods: Ninety Sprague 
Dawley rats were randomly divided into three groups. Group I served as control. Rats in Group II 
and III were made insulin resistant diabetics. Group III was treated with rosiglitazone after 
development of diabetes. Plasma glucose, serum triglycerides, HDL, TG:HDL ratio and serum 
resistin levels were analysed. Results: Body weight and plasma glucose were significantly increased 
(p<0.05) along with TG:HDL ratio (p<0.05) in group II and group III at the end of 4th week. Serum 
resistin levels also increased significantly (p<0.05) in group II and III at the end of 4th week. 
Treatment of group III with rosiglitazone led to improvement in insulin resistance with decrease in 
serum resistin levels (p<0.05). Conclusion: Increased serum resistin level indicates insulin resistance 
and impending hyperglycaemia. Thiazolidinediones augment sensitivity of insulin to restore 
normoglycaemia by decreasing serum resistin level. 
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INTRODUCTION 
Adipose tissue secretes various adipocytokines, 
including adiponectin, interleukin-6, leptin, resistin, 
TNF-α, visfatin and resistin which play an important 
role in pathogenesis of insulin resistance and 
cardiovascular disease.1 Resistin is one of the factors 
which affects peripheral insulin resistance. Serum 
resistin levels were found to be elevated in two different 
genetic models of mice and in a diet-induced model of 
insulin resistance and obesity.2 In the fructose-fed rat 
model of insulin resistance, resistin mRNA levels were 
increased.3 Mice exhibiting decreased adiposity and 
improved insulin sensitivity, were found to have 
decreased serum resistin levels.4 
Most individuals appear to develop insulin 
resistance when environmental factors interact with 
specific genetic predispositions that confer 
susceptibility.5 These include abnormalities of 
nutritional intake, obesity and decreased physical 
activity. Obesity is one of the key environmental factors 
responsible for the development of insulin resistance as 
it leads to increased production of adipocytokines such 
as resistin. This indicates the role of resistin in 
regulating insulin sensitivity. If resistin is involved in 
the pathogenesis of insulin resistance, it can be predicted 
that insulin sensitizing agents like thiazolidinediones 
may decrease resistin expression. Resistin mRNA and 
protein are down regulated by antidiabetic 
thiazolidinediones (TZDs) in adipocytes.6–8 The present 
study was designed to evaluate resistin levels after 
treatment with thiazolidinediones and effect on insulin 
resistant diabetes. 
SUBJECTS AND METHODS 
The project and relevant regulations governing the study 
were approved by the committee for postgraduate 
studies, Army Medical College, Rawalpindi. 
The study was conducted from January to July 
2010 at Army Medical College, Rawalpindi in 
collaboration with National Institute of Health (NIH), 
Islamabad. Ninety healthy Sprague Dawley rats with an 
average weight of 250±50 gm were procured from 
animal house of NIH, Islamabad. They were kept in its 
animal house facility where the temperature was 
maintained at 22±3 °C. Food and water was available ad 
libitum. The rooms were well ventilated and 12-hour 
light-dark cycle was maintained.  
By convenient sampling the rats (n=90) were 
divided into 3 equal groups (n=30 in each group). 
Weight of the animals was recorded and blood samples 
for baseline fasting blood glucose and serum resistin 
levels, triglycerides and HDL were taken by tail bleed. 
Group I served as control without any intervention and 
fed on normal diet. Rats in group II and III were fed on 
a high sucrose diet (Table-1) for 4 weeks to induce 
insulin resistance. Insulin resistance was measured by 
the triglycerides-to-high density lipoproteins (TG/HDL) 
ratio; being considered as one of the surrogate markers 
for insulin resistance. Blood sampling was done at the 
end of 4th week by tail bleed to confirm the presence of 
insulin resistance. After confirmation of development of 
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insulin resistance, rats in group III were treated with 
rosiglitazone injected intraperitoneally, 5 mg/Kg body 
weight for seven days. At the end of 5th week terminal 
sampling was done by intra cardiac bleed under ether 
anesthesia and the animals sacrificed. The plasma and 
serum samples were stored at –80 °C till assay of 
plasma glucose, serum triglycerides, HDL, TG:HDL 
ratio, and resistin levels.  
Table-1: Composition of rat diet 
Ingredients Weight* 
Vitamin A 10,000 IU/Kg 
Vitamin D 5,000 IU/Kg 
Vitamin E 50 mg/Kg 
Choline 800 mg/Kg 
Methionine 500 mg/Kg 
Sodium chloride 5 gm/Kg 
Dibasic Calcium Phosphate 9.5 gm/Kg 
Zinc Sulphate 24 mg/Kg 
Potassium Iodide 3 mg/Kg 
Total weight=amount of the premix added in 10 Kg of the pelleted 
diet prepared. *amount added/Kg of the diet prepared 
Data were analysed on SPSS-13. The 
arithmetic mean and standard deviation of all samples 
were calculated. Difference in mean among control and 
treated groups was calculated by Independent sample t-
test. Groups were compared using Analysis of Variance 
(ANOVA). Tukey test was used for Post Hoc 
Comparison; and p<0.05 was chosen as the limit for 
statistical significance. 
RESULTS 
Serum resistin levels in groups II and III were found to 
be significantly increased (p<0.05) at the end of 4 weeks 
(Table-2), after the development of insulin resistance by 
high sucrose diet. Serum resistin levels increased to 
21.75±2.92 ηg/ml in group II. In group III the serum 
resistin level increased to 20.94±2.29 ηg/ml (p<0.05) 
after the intake of high sucrose diet for four weeks as 
compared to the control (12.43±3.01 ηg/ml). 
Rosiglitazone treatment significantly decreased (p<0.05) 
resistin levels in group III from 20.94±2.29 ηg/ml to 
14.48±2.19 ηg/ml. 









Serum resistin 4th week 12.11±3.01 21.75±2.92 20.94±2.29 
Serum resistin 5th week 12.11±3.01 21.71±2.88 14.48±2.19 
DISCUSSION 
The relationship between obesity, insulin resistance, and 
cardiovascular diseases has been recognized since long 
but the mechanisms for their interrelationship are 
indistinct. Feeding of high sucrose diet for a period of 4 
weeks led to the increased body weight, hyperglycemia 
and increased Tg:HDL ratio in insulin resistant model as 
compared to the healthy control. A decrease in insulin 
sensitivity accompanied the hyper triglyceridemia in 
Sprague Dawley rats after 4 weeks of high sucrose diet. 
Adipose tissue mass increased due to high sucrose diet. 
Adipocytes are the source of adipocytokines including 
resistin. Resistin has been documented to antagonize the 
actions of insulin. The demonstration in this study that 
sucrose feeding produces insulin resistance is 
comparable to the findings of other studies carried out in 
high fructose and high sucrose fed rats, in which 
different techniques were used to assess insulin 
resistance.9–11 Serum resistin levels were increased in 
insulin resistant rats due to the increase in adipose tissue 
mass and body weight. It is well known that adipocytes 
secrete resistin. It is possible that resistin could lead to 
insulin resistance.  
According to Curat et al11, resistin expression 
in vivo is specific to white adipose tissue, and it is found 
in the serum of normal mice. Resistin is an adipocyte 
derived factor that contributes to the development of 
insulin resistance in vivo and has been supported by the 
studies on adipocytes, where neutralization with resistin 
antiserum enhanced insulin-stimulated glucose uptake. 
Administration of resistin to mice impairs the glucose 
tolerance without reducing insulin levels, and decreases 
sensitivity to the effects of insulin. Our study supported 
these findings that resistin is a hormone having effects 
on glucose metabolism which is antagonistic to those of 
insulin and thiazolidinediones improve insulin 
resistance by decreasing resistin levels. A significant 
correlation does exist between fasting glucose and 
serum resistin level. These findings are comparable to 
the previous study by Lazar et al12 on the rodent model 
in which fasting blood glucose level was higher in 
resistin transgenic mice than in their non-transgenic 
littermates, and glucose  tolerance was impaired in the 
hyper-resistinemic mice. 
Thiazolidinediones represents an important 
breakthrough in the therapy of insulin resistance, and 
their ability to down regulate resistin level suggests that 
there exists a link among resistin, insulin resistance and 
the mechanism of action of thiazolidinediones. 
Therefore, potential complications of PPARγ activation 
in tissues13 may be avoided by making resistin the target 
of insulin resistance therapy if regulation and properties 
of human resistin are similar to those of rat resistin. 
CONCLUSION 
Increased serum resistin levels indicate insulin resistance 
and impending hyperglycemia. Thiazolidinediones 
augment sensitivity of insulin to restore normoglycemia 
by decreasing serum resistin level. 
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